St John-Campbell Sahra, Bhalay Gurdip
Centre for Cancer Drug Discovery, The Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, United Kingdom.
J Med Chem. 2025 Jun 26;68(12):12331-12368. doi: 10.1021/acs.jmedchem.4c03115. Epub 2025 Jun 4.
In target-based drug discovery, quantification of target engagement is required to build structure-activity relationships and develop a potent clinical candidate. Target engagement data also provides evidence of a drug's mechanism of action (MoA) which although is not required for approval, can increase the chance of a successful clinical outcome. Consequently, a plethora of assays has been developed to provide information about target engagement on isolated proteins and in cells. These techniques monitor changes in stability, structure, optical properties or mass difference between proteins and their complexes with ligands. They also provide characterization of the compound with thermodynamic, kinetic and structural binding parameters. The diversity of approaches reflects the challenges faced when drugging different protein classes, with each method having advantages, trade-offs and target specificity.
在基于靶点的药物研发中,需要对靶点结合情况进行定量分析,以建立构效关系并开发出有效的临床候选药物。靶点结合数据还能提供药物作用机制(MoA)的证据,虽然这并非获批所必需,但可增加临床成功的几率。因此,已经开发了大量的分析方法,以提供关于在分离的蛋白质和细胞中靶点结合情况的信息。这些技术可监测蛋白质及其与配体的复合物之间稳定性、结构、光学性质或质量差异的变化。它们还能通过热力学、动力学和结构结合参数对化合物进行表征。方法的多样性反映了针对不同蛋白质类别进行药物研发时所面临的挑战,每种方法都有其优点、权衡之处和靶点特异性。